BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 2,137 publications, many in top-tier journals such as Nature and Science.

The company also contributes to scientific communication by publishing the international research journal GigaScience.

BGI’s distinguished achievements have made a significant contribution to the development of genomics throughout the world.  BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own BGISEQ sequencing platform, economies of scale, and expert bioinformatics resources.

BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. BGI’s services and solutions are available in more than 60 countries and regions around the world.


Trans-omics for a better life.


A combination of its high-throughput, cost-effective genomics platform, its large sample collection and storage capability, in-depth bioinformatics analysis, a core commitment to education and media liaison, a team of talents to support its scientific research program, has made BGI a unique entity dedicated to ensuring that omics science and technology can be made to work for the benefit of everyone.

As a leading biotechnology organization, BGI attempts to provide innovative biological research and application services, on an international level, to researchers and diagnosticians as well as ordinary people. In order to support dedicated efforts to promote applications in different fields, nine sub-organizations of BGI were spawned in 2012.

BGI Research

Relying on innovative integration of platforms to achieve major scientific breakthroughs in the basic research area and lead technology development, BGI Research is dedicated to improving the lives of ordinary people by facilitating scientific and technological advancement.

BGI Tech

As a premier scientific partner, BGI Tech is committed to providing high quality and innovative solutions for biological, agricultural and medical research.

BGI Tech aims to improve human health, resource saving and environmental protection by making leading technology available to researchers worldwide, promoting the dissemination of cutting edge science to the general public, building a global collaborative network and developing the foundation for a BGI knowledgebase.

BGI Diagnosis

BGI Diagnosis is devoted to extending the latest scientific advancements to the sphere of clinical testing and diagnosis and other healthcare-related fields, in order to prevent birth defects and genetic diseases and serve people a better life.

BGI Agriculture

BGI Agriculture is dedicated to the construction of an international state-of-the-art biotechnological breeding platform and applying scientific and technology advances to boost food production.

BGI Agriculture aims to improve human health and agricultural economics by producing sustainable high-performance cultivars based on advanced–omics technologies and by forming new industrial supply chains within agriculture.

BGI College

Adopting a well-rounded educational approach and employing an innovative model of talent training, BGI College is building a sophisticated international college to foster interdisciplinary scientific research.

BGI College is also establishing an innovative cross-sector educational platform to provide high quality education resources and train talents in bioscience and bioindustry.


BGI Manufacturing is focused on the development, production and sales of in vitro diagnostic reagents, medical devices, research reagents and equipments. China Food and Drug Administration (CFDA) has approved the registrations of BGI Manufacturing’s sequencers BGISEQ-1000 and BGISEQ-100. BGI became the first organization with the registration of next generation sequencing diagnostic products and medical devices.

China National GeneBank (Shenzhen)

Established by BGI-Shenzhen, the China National Genebank (CNGB) is the first national genebank integrating a large-scale bio-repository and an omics database. It is approved by Chinese government, with the mission of collecting, preserving and exploiting genomics resources, and to build a network fostering global communication and collaboration on biodiversity conservation and genetic resources utilization. In addition, CNGB is supported by BGI’s high-throughput sequencing and bio-informatics capacity, and it will not only provide a repository system for biological collection, but more importantly develop a novel platform to further understand genomic mechanisms of life.

Complete Genomics

Complete Genomics was established in 2005, now a wholly-owned subsidiary of BGI. Complete Genomics platform combined its proprietary human genome sequencing technology with advanced informatics and data management software. Researchers receive highly accurate genomic data, assembled and annotated, ready for their high-throughput sequencing projects.


GigaScience is a new open-access open-data journal for the publication of all types of biological studies that use or create large-scale data sets. With the goal of revolutionizing data accessibility, dissemination, organization, and use, GigaScience has a unique format that integrates article publication with the data-hosting and cloud-computing resources. As a part of the data-hosting services, GigaScience also has the ability to give important associated datasets Digital Object Identifiers (DOIs), making them easier to access, track and cite.

GigaScience aims to increase transparency and reproducibility of research, and emphasizes data quality and utility over subjective assessments of immediate impact.

BGI is headquartered in Shenzhen, with services and solutions available in more than 100 countries and regions around the world.

Click here to view the original picture


BGI has a proven track record of excellence, delivering results with high accuracy and efficiency to support innovative, high-profile research which has so far generated over 2,097 publications in top-tier journals such as Nature and Science. These accomplishments include sequencing one percent of the human genome for the International Human Genome Project, sequencing the first Asian diploid genome, contributing 10 percent to the International Human HapMap Project, sequencing a significant proportion of the genomes for the 1,000 Genomes Project, carrying out vital research to combat SARS and the German deadly E. coli O104:H4 strain, playing a key role in the Sino-British Chicken Genome Project, completing the genomic sequences of rice, silkworm, potato, the human Gut metagenome, etc.

BGI has developed a systematic research platform based on the combination of biotechnology and information technology, including high-throughput sequencing, proteomics, cell biology, genetic engineering and bioinformatics. It acts as a core unit to participate in national genebank construction, and has established reproductive health centers and clinical testing centers to further promote genetic testing applications to healthcare services,  as well as environmental applications and molecular breeding.

BGI aims to develop research collaborations and provide scientific support to scientists worldwide, thereby contributing to the advancement of innovative biological research, molecular breeding and improved healthcare. BGI is committed to facilitating research applications in the spheres of healthcare, agriculture, and environmental preservation, to improve and enrich people’s lives.